# Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis

> **NCT00459537** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 1029 (actual)

## Conditions studied

- Onychomycosis

## Interventions

- **DRUG:** terbinafine hydrogen chloride
- **DRUG:** amorolfine nail lacquer

## Key facts

- **NCT ID:** NCT00459537
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 1029 (ACTUAL)
- **Last updated:** 2011-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00459537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00459537, "Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00459537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*